Showing 2591-2600 of 5693 results for "".
- Supreme Court to Hear Arguments on Pivotal Case That Decides Fate of ACA After Electionhttps://modernod.com/news/supreme-court-to-hear-arguments-on-pivotal-case-that-decides-fate-of-aca-after-election/2478180/The Supreme Court will hear oral arguments in a lawsuit over the constitutionality of the Affordable Care Act (ACA) on November 10, a week after the presidential election, according to a FierceHealthcare
- Regeneron Boosts Production Capacity for COVID-19 Antibody Cocktail Via Deal With Rochehttps://modernod.com/news/regeneron-boosts-production-capacity-for-covid-19-antibody-cocktail-via-deal-with-roche/2478176/Regeneron Pharmaceuticals said that the overall capacity to produce REGN-COV2, a two-antibody cocktail against COVID-19, will increase by at least 3.5 times under a development and manufacturing collaboration with Roche. As part of the deal, Regeneron will market REGN-COV2 in the US, with Roche r
- Sanofi Enters $3.7-Billion Deal to Buy Principia Biopharmahttps://modernod.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/Sanofi announced Monday a definitive agreement to acquire all of Principia Biopharma’s outstanding stock for $100 per share in cash, representing an equity value of around $3.7 billion, boosting the French drugmaker’s core research areas of autoimmune and allergic diseases. The deal,
- Diagnostic Market Sees New Demand Due to Effects of COVID-19https://modernod.com/news/diagnostic-market-sees-new-demand-due-to-effects-of-covid-19/2478150/Increasing demand for telehealth and mobile applications due to the COVID-19 pandemic has led manufacturers to scramble to add functionality and accessibility to existing devices and protection apparatuses or create new devices, according to a Market Scope report. Regulatory bodies and re
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and
- Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Koreahttps://modernod.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Tai
- Serum Institute to Produce COVID-19 Vaccines From AstraZeneca, Novavaxhttps://modernod.com/news/serum-institute-to-produce-covid-19-vaccines-from-astrazeneca-novavax/2478139/The Serum Institute of India (SII) said it will produce coronavirus vaccines from AstraZeneca and Novavax, making them available for procurement, if they gain marketing approval, at a ceiling price of $3 per dose. SII noted that it will use funding from Gavi, The Vaccine Alliance and the Bill &am
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th
- EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/EyePoint Pharmaceuticals and ImprimisRx announced the signing of a commercial alliance for the joint promotion of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the United States.
- Sanofi, GSK Gain $2.1 Billion From US Government for Development, Supply of COVID-19 Vaccinehttps://modernod.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/Sanofi and GlaxoSmithKline announced that the US government will provide more than $2.1 billion to support further development, manufacturing and delivery of initial doses of the companies’ adjuvanted vaccine against COVID-19. The vaccine candidate is based on Sanofi’s recombinant pro